Adjuvant sunitinib or sorafenib don’t prevent recurrence of kidney cancer

Results from the ASSURE clinical trial have recently been published in the Lancet. ASSURE compared the effect of adjuvant sorafenib or sunitinib with placebo in renal cell carcinoma (RCC) patients who had had their tumours surgically removed, and who had a high risk for recurrence. The trial was conducted in the US and Canada, and initial […]

read more

Scientists use natural killer (NK) cells to fight cancer

Researchers in Australia have identified a mechanism that blocks natural killer (NK) cells, a type of immune cell, from attacking cancer. Switching off this mechanism had a dramatic effect on mice with skin, prostate and breast cancers: The action of the NK cells against the cancer cells in the tumours was stepped up. This prevented the spread of cancer […]

read more

Cabozantinib improves progression-free survival in renal cell carcinoma

Results from the phase II CABOSUN trial, released this week, have shown that cabozantinib (Cabometyx) significantly improved progression-free survival (PFS) compared with sunitinib (Sutent) in advanced renal cell carcinoma (RCC) patients who had not received any previous drug treatment. The safety profile for cabozantinib was similar to that previously reported in advanced RCC. Cabozantinib, a […]

read more

Pfizer’s new cancer drug shows promise in combination with Merck’s Keytruda

Data from a small clinical trial were released last week to show that a combination of a new, experimental drug that helps the immune system fight cancer with the immunotherapy, Keytruda  showed early promise against a variety of cancers.  Immunotherapies, such as Merck’s Keytruda, block the mechanisms that tumours use to evade the immune system. […]

read more

FDA approves lenvatinib/everolimus combination for kidney cancer

The FDA has approved the combination of lenvatinib (Lenvima) and everolimus (Afinitor) as a treatment for patients with advanced renal cell carcinoma (RCC) following prior antiangiogeneic therapy, based on survival and response data from a phase II study. In the trial, known as Study 205, the combination of lenvatinib and everolimus reduced the risk of […]

read more

X4P-001 to begin phase 1/2 clinical trials

X4 Pharmaceuticals, a clinical stage US biotechnology company, has announced that the first patient has been enrolled and dosed in a phase 1/2 study of X4P-001, a CXCR4 inhibitor. CXCR4 inhibitor drugs improve immune cell trafficking and increase the ability for T-cells to track and destroy cancer. The phase 1 portion of the study will […]

read more

Modifiable risk factors for kidney cancer

A healthy lifestyle can make a direct, positive and beneficial change to one’s life. As such, four new studies proving that diet, exercise and maintaining a healthy weight helps to improve your urologic health, were presented during a special press conference at the 111th Annual Scientific Meeting of the American Urological Association (AUA) held in […]

read more

Immunotherapy before and after surgery for kidney cancer

At the American Urological Association’s Annual Meeting in San Diego this week, Dr Harshman spoke about treating renal cell carcinoma (RCC) before and after surgery with immunotherapy. Although results from the EVEREST trial and others are eagerly anticipated, there has been no major success using adjuvant therapies (treatment after surgery) in kidney cancer to date. […]

read more

Common supplement boosts kidney cancer therapy

A recent study published in the journal Molecular Cancer Therapeutics by researchers at University College Davis Comprehensive Cancer Center in the US, shows that docosahexaenoic acid (DHA), a fatty acid commonly found in fish and fish oil supplements, reduces the invasiveness of renal cell carcinomas (RCC), growth rate, and blood vessel growth when combined with […]

read more

Vaccines for renal cell carcinoma

This OncLive panel discussion focuses on the treatment of renal cell carcinoma (RCC) with vaccines, specifically the results from the ADAPT trial, and suggest that the way forward for vaccine treatment is in combination with other RCC drugs. They then move on to talk about combination trials with immunotherapy and TKI drugs; however, combinations of […]

read more
Showing 681 to 690 of 695 results
  TOP